NGM BIOPHARMACEUTICALS INC Variable Lease, Cost
NGM BIOPHARMACEUTICALS INC reported Variable Lease, Cost of $1.41 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2024-03-11
- NGM BIOPHARMACEUTICALS INC variable lease, cost for the quarter ending 2023-12-31 was $339.00K, a 4.63% increase year-over-year.
- NGM BIOPHARMACEUTICALS INC variable lease, cost for the quarter ending 2023-09-30 was $338.00K, a 7.64% increase year-over-year.
- NGM BIOPHARMACEUTICALS INC variable lease, cost for the quarter ending 2023-06-30 was $390.00K, a 20.37% increase year-over-year.
- NGM BIOPHARMACEUTICALS INC variable lease, cost for the quarter ending 2023-03-31 was $339.00K, a 4.63% increase year-over-year.
- NGM BIOPHARMACEUTICALS INC variable lease, cost for fiscal 2023 was $1.41M, a 9.33% increase from fiscal 2022.
- NGM BIOPHARMACEUTICALS INC variable lease, cost for fiscal 2022 was $1.29M, a 4.13% increase from fiscal 2021.
- NGM BIOPHARMACEUTICALS INC variable lease, cost for fiscal 2021 was $1.24M.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-12-31 | $339.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $677.00K derived: sum of 2 quarters · filed 2024-03-11 | $1.07M derived: sum of 3 quarters · filed 2024-03-11 | $1.41M 10-K · filed 2024-03-11 |
| 2023-09-30 | $338.00K 10-Q · filed 2023-11-02 | $728.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.07M 10-Q · filed 2023-11-02 | $1.39M derived: sum of 4 quarters · filed 2024-03-11 |
| 2023-06-30 | $390.00K 10-Q · filed 2023-08-03 | $729.00K 10-Q · filed 2023-08-03 | $1.05M derived: sum of 3 quarters · filed 2024-03-11 | $1.37M derived: sum of 4 quarters · filed 2024-03-11 |
| 2023-03-31 | $339.00K 10-Q · filed 2023-05-04 | $663.00K derived: sum of 2 quarters · filed 2024-03-11 | $977.00K derived: sum of 3 quarters · filed 2024-03-11 | $1.30M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-12-31 | $324.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $638.00K derived: sum of 2 quarters · filed 2024-03-11 | $962.00K derived: sum of 3 quarters · filed 2024-03-11 | $1.29M 10-K · filed 2024-03-11 |
| 2022-09-30 | $314.00K 10-Q · filed 2023-11-02 | $638.00K derived: sum of 2 quarters · filed 2023-11-02 | $962.00K 10-Q · filed 2023-11-02 | $1.27M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $324.00K 10-Q · filed 2023-08-03 | $648.00K 10-Q · filed 2023-08-03 | $957.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.26M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $324.00K 10-Q · filed 2023-05-04 | $633.00K derived: sum of 2 quarters · filed 2023-05-04 | $941.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.25M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $309.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $617.00K derived: sum of 2 quarters · filed 2023-02-28 | $926.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.24M 10-K · filed 2023-02-28 |
| 2021-09-30 | $308.00K 10-Q · filed 2022-11-03 | $617.00K derived: sum of 2 quarters · filed 2022-11-03 | $926.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $309.00K 10-Q · filed 2022-08-04 | $618.00K 10-Q · filed 2022-08-04 |